Pharmaceuticals, Biotechnology and Life Sciences
Verona Pharma has dosed the first patient in a phase 2a test of its candidate RPL554 for cystic fibrosis, the most common fatal inherited disease in the United States and Europe.
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …
Horizon Pharma and its Canadian affiliate Horizon Therapeutics Canada Limited have brought its inhalation solution for chrnic lung infection Quinsair to Canada.
Quinsair is used for chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).
Galapagos has reported topline results from its Saphira 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.
Vertex Pharmaceuticals Incorporated today announced the results of a Phase 3 study of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis…
The European Commission has approved expansion of the indication for Vertex Pharmaceuticals’ Kalydeco, to include children ages 2-5 with cystic fibrosis…